Single Dose Crossover Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules in Healthy Male Volunteers Following Administration of a 50 mg Dose / Fasted and Fed States
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Opicapone (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Bial
- 27 Jun 2017 Results presented at the 3rd Congress of the European Academy of Neurology
- 08 Jun 2017 Results (n=40) assessing effect of food on the pharmacokinetics and pharmacodynamics of opicapone after single and repeated doses using patient data from NCT02071823 and NCT03116308 trials, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
- 14 Apr 2014 New source identified and integrated; ClinicalTrials.gov record (NCT02071823)